I-Mab to Participate at the Truist Securities BioPharma Symposium
I-Mab(IMAB) Prnewswire·2024-10-28 19:00
ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024. Event Details Meeting Date Thursday, November 7, 2024 Meetings One-on-one and small group meetings: November 7, 2024 Sean Fu, PhD ...